<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Procainamide: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Procainamide: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Procainamide: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9813" href="/d/html/9813.html" rel="external">see "Procainamide: Drug information"</a> and <a class="drug drug_patient" data-topicid="11411" href="/d/html/11411.html" rel="external">see "Procainamide: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5709347"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Drug-induced lupus erythematosus-like syndrome:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">The prolonged administration of procainamide often leads to the development of a positive antinuclear antibody (ANA) test, with or without symptoms of a lupus erythematosus-like syndrome. If a positive ANA titer develops, the benefits versus risks of continued procainamide therapy should be assessed.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Mortality:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">In the National Heart, Lung and Blood Institute's Cardiac Arrhythmia Suppression Trial (CAST), a long-term, multicenter, randomized, double-blind study in patients with asymptomatic non-life-threatening ventricular arrhythmias who had myocardial infarction more than 6 days but less than 2 years previously, an excessive mortality or nonfatal cardiac arrest rate (7.7%) was seen in patients treated with encainide or flecainide compared with that seen in patients assigned to matched placebo-treated group (3%). The average duration of treatment with encainide or flecainide in this study was 10 months.</p>
<p style="text-indent:-2em;margin-left:2em;">The applicability of the CAST results to other populations (eg, those without recent myocardial infarctions) is uncertain. Considering the known proarrhythmic properties of procainamide and the lack of evidence of improved survival for any antiarrhythmic drug in patients without life-threatening arrhythmias, the use of procainamide as well as other antiarrhythmic agents should be reserved for patients with life-threatening ventricular arrhythmias.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Blood dyscrasias:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Agranulocytosis, bone marrow depression, neutropenia, hypoplastic anemia and thrombocytopenia in patients receiving procainamide HCl have been reported at a rate of approximately 0.5%. Most of these patients received procainamide within the recommended dosage range. Fatalities have occurred (with approximately 20 to 25% mortality in reported cases of agranulocytosis). Since most of these events have been noted during the first 12 weeks of therapy, it is recommended that complete blood counts including white cell, differential and platelet counts be performed at weekly intervals for the first 3 months of therapy, and periodically thereafter. Complete blood counts should be performed promptly if the patient develops any signs of infection (such as fever, chills, sore throat or stomatitis), bruising or bleeding. If any of those hematologic disorders are identified, procainamide therapy should be discontinued. Blood counts usually return to normal within 1 month of discontinuation. Caution should be used in patients with preexisting marrow failure or cytopenia of any type.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1055112"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antiarrhythmic Agent, Class I-A</span></li></ul></div>
<div class="block don drugH1Div" id="F53462558"><span class="drugH1">Dosing: Neonatal</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Dose must be individualized and titrated to patient's response; monitor serum concentrations.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9f882e79-d62c-4b63-bf32-63cd49609f40">Supraventricular tachycardia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Supraventricular tachycardia:</b> Limited data available: IV: Loading dose: 7 to 10 mg/kg infused over 60 minutes followed by a continuous IV infusion of 20 to 80 <b>mcg</b>/kg/minute; dosing based on a retrospective study of 20 neonates (GA: ≥25 weeks) reported a mean loading dose of 9.6 ± 1.5 mg/kg and a mean continuous infusion rate of 37.56 ± 13.52 <b>mcg</b>/kg/minute; <b>Note:</b> Procainamide serum concentrations were supratherapeutic in 5 neonates studied; 4 of the 5 were &lt;36 weeks GA and all 5 had CrCl &lt;30 mL/minute/1.73 m<sup>2</sup>; these results indicate that doses may need to be decreased in preterm neonates and in those with renal impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17125432']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17125432'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F213566"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Cardiology consultation strongly recommended prior to use; use caution when administering procainamide with other drugs that prolong QT interval (eg, amiodarone). Dose must be individualized and titrated based on patient's blood pressure, ECG, and arrhythmia control; monitor serum concentrations (procainamide and N-acetylprocainamide [NAPA]) and QRS complex to avoid toxicity.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b1d5ffb6-1b4a-41f4-b7c1-6e3e84754892">Tachyarrhythmia, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Tachyarrhythmia (including junctional ectopic tachycardia [JET], supraventricular tachycardia [SVT], atrial fibrillation, and atrial flutter), treatment:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">IV, Intraosseous:</p>
<p style="text-indent:-2em;margin-left:8em;">Loading dose: <b>Note: </b>Monitor telemetry and blood pressure closely during administration; if arrhythmia terminates, consider discontinuing loading dose; discontinue or hold loading dose if blood pressure drops below acceptable range:</p>
<p style="text-indent:-2em;margin-left:10em;">10 to 15 mg/kg as a single dose infused over 30 to 60 minutes (maximum total loading dose: 500 mg) <b>or</b> the total loading dose may also be divided and given in 2 to 6 mg/kg/dose increments (up to 100 mg/dose) infused over ≥5 minutes and may be repeated every 10 to 30 minutes as needed; maximum adult total loading dose: 1,000 mg; may follow with continuous infusion as clinically appropriate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31871244','lexi-content-ref-29685887','lexi-content-ref-20194798','lexi-content-ref-1089243','lexi-content-ref-Kliegman.1','lexi-content-ref-9391691','lexi-content-ref-10754080','lexi-content-ref-Park.1','lexi-content-ref-9120158','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31871244','lexi-content-ref-29685887','lexi-content-ref-20194798','lexi-content-ref-1089243','lexi-content-ref-Kliegman.1','lexi-content-ref-9391691','lexi-content-ref-10754080','lexi-content-ref-Park.1','lexi-content-ref-9120158','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Maintenance: Continuous IV infusion: 20 to 80 <b>mcg</b>/kg/minute; maximum daily dose: 2,000 mg/24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31871244','lexi-content-ref-1089243','lexi-content-ref-Kliegman.1','lexi-content-ref-9391691','lexi-content-ref-Park.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31871244','lexi-content-ref-1089243','lexi-content-ref-Kliegman.1','lexi-content-ref-9391691','lexi-content-ref-Park.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Oral: 15 to 50 mg/kg/<b>day </b>divided every 3 to 6 hours; maximum daily dose: 4,000 mg/24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kliegman.1','lexi-content-ref-Park.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kliegman.1','lexi-content-ref-Park.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="27475192-bdee-4084-8899-45d46f2689d9">Resuscitation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Resuscitation (Pediatric Advanced Life Support [PALS]): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Supraventricular tachycardia, hemodynamically unstable and shock-refractory </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20956230']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20956230'])">Ref</a></span>): Limited data available:</p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents: IV, Intraosseous: 15 mg/kg infused over 30 to 60 minutes, rate of infusion depends on urgency of clinical scenario; may give additional doses if clinical endpoint not achieved and no signs of toxicity exist; monitor ECG and blood pressure.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Wide-complex tachycardia of unknown origin (atrial or ventricular), hemodynamically stable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20956230']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20956230'])">Ref</a></span>)</b>: Limited data available:</p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents: IV, Intraosseous: 15 mg/kg infused over 30 to 60 minutes; monitor ECG and blood pressure; stop the infusion if hypotension occurs or QRS complex widens by &gt;50% of baseline.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51154967"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Infants, Children, and Adolescents: There are no specific recommendations provided in the manufacturer's labeling; dose must be individualized and titrated to patient's response; close monitoring of procainamide and N-acetylprocainamide (NAPA) serum concentrations, if facilities are available for measurement, and clinical effectiveness recommended. Some have suggested the following (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>): <b>Note: </b>Renally adjusted dose recommendations are based on a dose of loading dose of 15 mg/kg total.</p>
<p style="text-indent:-2em;margin-left:4em;">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>:</p>
<p style="text-indent:-2em;margin-left:6em;">Loading dose: Reduce dose to 12 mg/kg</p>
<p style="text-indent:-2em;margin-left:6em;">Maintenance infusion: Start at lower end of continuous infusion range of 20 to 80 <b>mcg</b>/kg/minute</p>
<p style="text-indent:-2em;margin-left:2em;">Dialysis: All patients:</p>
<p style="text-indent:-2em;margin-left:4em;">Procainamide: Moderately hemodialyzable (20% to 50%): Monitor procainamide/NAPA levels; supplementation may be necessary</p>
<p style="text-indent:-2em;margin-left:4em;">NAPA: Not dialyzable (0% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Procainamide/NAPA: Not peritoneal dialyzable (0% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Procainamide/NAPA: Replace by blood level during continuous arteriovenous or venovenous hemofiltration</p></div>
<div class="block dohp drugH1Div" id="F51284868"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no pediatric-specific recommendations; based on experience in adult patients, dosing adjustment suggested. Use with caution, closely monitor procainamide and NAPA concentrations.</p></div>
<div class="block doa drugH1Div" id="F213547"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9813" href="/d/html/9813.html" rel="external">see "Procainamide: Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing: </b>To calculate dose, some experts use actual body weight, and others use ideal body weight (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6191939']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6191939'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations:</b> Not recommended to treat cardiac arrest due to ventricular fibrillation or pulseless ventricular tachycardia due to lack of efficacy and prolonged administration time (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33081529','lexi-content-ref-29084731']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33081529','lexi-content-ref-29084731'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="91640887-fadd-4a17-b638-7bdd4d33b292">Atrial fibrillation with preexcitation, hemodynamically stable</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Atrial fibrillation with preexcitation, hemodynamically stable (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Loading dose: IV: </b>Initial: 20 to 50 mg/minute until a maximum of 17 mg/kg is administered, the arrhythmia is controlled, or hypotension occurs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20956224','lexi-content-ref-Hazinski.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20956224','lexi-content-ref-Hazinski.1'])">Ref</a></span>). Some experts do not exceed 15 mg/kg or a maximum dose of 1.5 g (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Prutkin.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Prutkin.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Maintenance infusion:</b>
<b>Note: </b>Once the arrhythmia terminates, seek an alternative agent for ongoing management; use of procainamide for more than 12 to 24 hours is associated with significant toxicity (eg, torsades de pointes) and requires monitoring by an experienced clinician (eg, QRS interval, QTc interval, procainamide and N-acetyl procainamide serum concentrations) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Prutkin.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Prutkin.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Continuous infusion: IV:</b> 1 to 4 mg/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20956224','lexi-content-ref-Hazinski.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20956224','lexi-content-ref-Hazinski.1'])">Ref</a></span>). Some experts use higher infusion rates (eg, up to 6 to 10 mg/minute) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Prutkin.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Prutkin.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7bcce71e-4ee1-4504-873b-6fbb200ad5d8">Atrioventricular reentrant tachycardia, antidromic or orthodromic, hemodynamically stable</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Atrioventricular reentrant tachycardia, antidromic or orthodromic, hemodynamically stable (off-label use</b>
<b>):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Procainamide is a preferred agent for acute treatment of antidromic atrioventricular reentrant tachycardia (AVRT). In known orthodromic AVRT, procainamide is an alternative to atrioventricular nodal blocking agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31504425']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31504425'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Loading dose: IV: </b>Initial: 20 to 50 mg/minute until a maximum of 17 mg/kg is administered, arrhythmia is controlled, or hypotension occurs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20956224','lexi-content-ref-Hazinski.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20956224','lexi-content-ref-Hazinski.1'])">Ref</a></span>). Some experts do not exceed 15 mg/kg or a maximum dose of 1.5 g (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Prutkin.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Prutkin.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Maintenance infusion:</b>
<b>Note: </b>Once the arrhythmia terminates, seek an alternative agent for ongoing management; use of procainamide for more than 12 to 24 hours is associated with significant toxicity (eg, torsades de pointes) and requires monitoring by an experienced clinician (eg, QRS interval, QTc interval, procainamide, N-acetyl procainamide serum concentrations) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Prutkin.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Prutkin.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Continuous infusion: IV:</b> 1 to 4 mg/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20956224','lexi-content-ref-Hazinski.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20956224','lexi-content-ref-Hazinski.1'])">Ref</a></span>). Some experts use higher infusion rates (up to 6 to 10 mg/minute) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Prutkin.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Prutkin.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ad2e5fe9-071f-461d-b6f9-af571f072010">Ventricular tachycardia, hemodynamically stable, sustained monomorphic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ventricular tachycardia, hemodynamically stable, sustained monomorphic:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Loading dose: IV: </b>Initial: 20 to 50 mg/minute until a maximum of 17 mg/kg is administered, arrhythmia is controlled, or hypotension occurs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33081529','lexi-content-ref-29084731']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33081529','lexi-content-ref-29084731'])">Ref</a></span>). Some experts do not exceed 15 mg/kg or a maximum dose of 1.5 g (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Prutkin.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Prutkin.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Maintenance infusion:</b>
<b>Note: </b>Once the arrhythmia terminates, seek an alternative agent for ongoing management; use of procainamide for more than 12 to 24 hours is associated with significant toxicity (eg, torsades de pointes) and requires monitoring by an experienced clinician (eg, QRS interval, QTc interval, procainamide, N-acetyl procainamide serum concentrations) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Prutkin.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Prutkin.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Continuous infusion: IV:</b> 1 to 4 mg/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20956224','lexi-content-ref-29084731','lexi-content-ref-Hazinski.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20956224','lexi-content-ref-29084731','lexi-content-ref-Hazinski.1'])">Ref</a></span>). Some experts use up to 6 to 10 mg/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Prutkin.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Prutkin.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991568"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note: </b>Monitor procainamide and N-acetyl procainamide (NAPA) concentrations.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &gt;50 mL/minute: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bauer.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bauer.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 10 to 50 mL/minute: Reduce continuous infusion dose by 25% to 50% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bauer.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bauer.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;10 mL/minute: Reduce continuous infusion dose by 50% to 75% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bauer.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bauer.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Procainamide: Moderately hemodialyzable (20% to 50%); NAPA: Not dialyzable (0% to 5%): supplementation may be necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis: </b> Not significantly dialyzable (procainamide and NAPA) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> Reduce maintenance dose by 50%. In patients with anuria receiving CRRT, further dosage reduction may be required (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23562328']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23562328'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988686"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note: </b>Monitor procainamide and N-acetyl procainamide concentrations.</p>
<p style="text-indent:-2em;margin-left:2em;">Child-Pugh score 8 to 10: Reduce continuous infusion dose by 25% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bauer.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bauer.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Child-Pugh score &gt;10: Reduce continuous infusion dose by 50% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bauer.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bauer.1'])">Ref</a></span>).</p></div>
<div class="block adr drugH1Div" id="F213508"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Positive ANA titer (≤50%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Lupus-like syndrome (≤30%, increased incidence with long-term therapy or slow acetylators; syndrome may include abdominal pain, arthralgia, arthritis, chills, fever, hepatomegaly, myalgia, pericarditis, pleural effusion, pulmonary infiltrates, skin rash)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypotension (intravenous: ≤5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (oral: 3% to 4%), dysgeusia (oral: 3% to 4%), nausea (oral: 3% to 4%), vomiting (oral: 3% to 4%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Agranulocytosis, angioedema, anorexia, aplastic anemia, arthralgia, asystole, bone marrow depression, cerebellar ataxia, confusion, demyelinating disease (demyelinating polyradiculoneuropathy), depression, depression of myocardial contractility, disorientation, dizziness, drug fever, exacerbation of cardiac arrhythmia, exacerbation of myasthenia gravis, fever, first degree atrioventricular block, flushing, gastrointestinal pseudo-obstruction, granulomatous hepatitis, hallucination, hemolytic anemia, hepatic failure, hyperbilirubinemia, hypoplastic anemia, increased serum alkaline phosphatase, increased serum transaminases, intrahepatic cholestasis, leukopenia, maculopapular rash, mania, myocarditis, myopathy, neuromuscular blockade, neutropenia, pancreatitis, pancytopenia, peripheral neuropathy, pleural effusion, polyneuropathy, positive direct Coombs test, prolonged QT interval on ECG, psychosis, pruritus, pulmonary embolism, second degree atrioventricular block, tachycardia, thrombocytopenia, torsades de pointes, urticaria, vasculitis, ventricular fibrillation, ventricular tachycardia (paradoxical; in atrial fibrillation/flutter), weakness</p></div>
<div class="block coi drugH1Div" id="F213525"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to procainamide, procaine, other ester-type local anesthetics, or any component of the formulation; complete heart block; second-degree AV block or various types of hemiblock (without a functional artificial pacemaker); systemic lupus erythematosus; torsade de pointes.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling: </i>Additional contraindications (not in US labeling): Myasthenia gravis; severe heart failure; kidney failure; shock.</p></div>
<div class="block war drugH1Div" id="F213505"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Blood dyscrasias:<b> [US Boxed Warning]: Potentially fatal blood dyscrasias (eg, agranulocytosis) have occurred with therapeutic doses;</b> weekly monitoring is recommended during the first 3 months of therapy and periodically thereafter. Discontinue procainamide if this occurs.</p>
<p style="text-indent:-2em;margin-left:4em;">• Conduction disturbances: Reduce dose if first-degree heart block occurs.</p>
<p style="text-indent:-2em;margin-left:4em;">• Drug-induced lupus erythematosus-like syndrome: <b>[US Boxed Warning]: Long-term administration leads to the development of a positive antinuclear antibody (ANA) test in 50% of patients which may result in a drug-induced lupus erythematosus-like syndrome (in 20% to 30% of patients);</b> discontinue procainamide with rising ANA titers or with SLE symptoms and choose an alternative agent.</p>
<p style="text-indent:-2em;margin-left:4em;">• Proarrhythmic effects: Watch for proarrhythmic effects; monitor and adjust dose to prevent QTc prolongation. Avoid use in patients with QT prolongation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Atrial fibrillation/flutter: May increase ventricular response rate in patients with atrial fibrillation or flutter; control AV conduction before initiating.</p>
<p style="text-indent:-2em;margin-left:4em;">• Electrolyte imbalance: Correct electrolyte disturbances, especially hypokalemia or hypomagnesemia, prior to use and throughout therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Heart failure: Use with caution or avoid in patients with heart failure; may precipitate or exacerbate condition due to negative inotropic actions.</p>
<p style="text-indent:-2em;margin-left:4em;">• Kidney impairment: Use with caution in patients with kidney impairment; dosage reduction recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">• Myasthenia gravis: Avoid use in myasthenia gravis; may worsen condition.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Sodium metabisulfite: The injectable product may contain sodium metabisulfite, which can cause allergic-type reactions, including anaphylactic symptoms and life-threatening asthmatic episodes in susceptible people; this is seen more frequently in patients with asthma.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use caution and dose cautiously; renal clearance of procainamide/N-acetyl procainamide declines in patients ≥50 years of age (independent of CrCl reductions) and in the presence of concomitant renal impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• CAST trial:<b> [US Boxed Warning] In the Cardiac Arrhythmia Suppression Trial (CAST), recent (&gt;6 days but &lt;2 years ago) myocardial infarction patients with asymptomatic, non-life-threatening ventricular arrhythmias did not benefit and may have been harmed by attempts to suppress the arrhythmia with flecainide or encainide.</b> An increased mortality or nonfatal cardiac arrest rate (7.7%) was seen in the active treatment group compared with patients in the placebo group (3%). The applicability of the CAST results to other populations is unknown. Procainamide should be reserved for patients with life-threatening ventricular arrhythmias.</p></div>
<div class="block foc drugH1Div" id="F213516"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg/mL (10 mL); 500 mg/mL (2 mL)</p></div>
<div class="block geq drugH1Div" id="F213501"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323724"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Procainamide HCl Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg/mL (per mL): $10.20 - $72.00</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg/mL (per mL): $360.00</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868032"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg/mL (10 mL)</p></div>
<div class="block admp drugH1Div" id="F52613673"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: IV: <b>Note:</b> Infusion rate should be decreased if QT interval becomes prolonged or patient develops heart block; discontinue the infusion if patient develops hypotension or QRS interval widens to &gt;50% of baseline; severe hypotension can occur with rapid IV administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20956230']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20956230'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Loading dose:</p>
<p style="text-indent:-2em;margin-left:6em;">Neonates: Administer over 60 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17125432']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17125432'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents: <b>Note: </b>Close monitoring is recommended to assess clinical response and adverse drug reactions; rate of administration varies depending on type of dosing; use precaution:</p>
<p style="text-indent:-2em;margin-left:8em;">Single loading dose (10 to 15 mg/kg up to 500 mg): Administer total dose over 30 to 60 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31871244','lexi-content-ref-29685887','lexi-content-ref-20956230']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31871244','lexi-content-ref-29685887','lexi-content-ref-20956230'])">Ref</a></span>); <b>Note: </b>Usual adult infusion rate: 20 to 50 mg/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hegenbarth.1','lexi-content-ref-20956230','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hegenbarth.1','lexi-content-ref-20956230','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Divided loading doses (2 to 6 mg/kg/dose up to 100 mg/dose): Administer over ≥5 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1089243','lexi-content-ref-Park.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1089243','lexi-content-ref-Park.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Continuous IV infusion: Administer via an infusion pump.</p></div>
<div class="block adm drugH1Div" id="F213521"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Loading dose: Administer at a rate of 20 to 50 mg/minute.</p>
<p style="text-indent:-2em;margin-left:4em;">Continuous infusion: Administer at a rate of 1 to 4 mg/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20956224','lexi-content-ref-29084731','lexi-content-ref-Hazinski.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20956224','lexi-content-ref-29084731','lexi-content-ref-Hazinski.1'])">Ref</a></span>).</p></div>
<div class="block sts drugH1Div" id="F213538"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store intact vials at 20°C to 25°C (68°F to 77°F). The solution is initially colorless but may turn slightly yellow on standing. Discard solutions darker than light amber.</p></div>
<div class="block usep drugH1Div" id="F53568507"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of life-threatening ventricular arrhythmias (FDA approved in adults); has also been used for treatment of tachyarrhythmias including supraventricular tachycardia (SVT).</p>
<p style="text-indent:-2em;margin-left:2em;">PALS guidelines: Tachycardia with pulses and poor perfusion (probable SVT [unresponsive to vagal maneuvers and adenosine and/or synchronized cardioversion]; probable ventricular tachycardia [unresponsive to synchronized cardioversion or adenosine]).</p></div>
<div class="block mst drugH1Div" id="F213591"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Procanbid may be confused with probenecid, Procan SR </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Pronestyl may be confused with Ponstel</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Administration issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Procainamide hydrochloride is available in 10 mL vials of 100 mg/mL and in 2 mL vials with 500 mg/mL. Note that <b>BOTH</b> vials contain 1 gram of drug; confusing the strengths can lead to massive overdoses or underdoses.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">PCA is an error-prone abbreviation (mistaken as patient controlled analgesia) </p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F213576"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2D6 (minor), OCT1, OCT2; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F213510"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Ajmaline: May enhance the QTc-prolonging effect of QT-prolonging Class IA Antiarrhythmics (Highest Risk). QT-prolonging Class IA Antiarrhythmics (Highest Risk) may increase the serum concentration of Ajmaline.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amiodarone: QT-prolonging Class IA Antiarrhythmics (Highest Risk) may enhance the QTc-prolonging effect of Amiodarone.  Management: Consider alternatives to this drug combination. If combined, consider dose reductions of the class IA antiarrhythmic (30% to 50%) and monitor for QTc interval prolongation and ventricular arrhythmias.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Amisulpride (Oral).  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even greater risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azithromycin (Systemic): QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Azithromycin (Systemic).  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Carbetocin: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ceritinib: May enhance the QTc-prolonging effect of QT-prolonging Class IA Antiarrhythmics (Highest Risk). QT-prolonging Class IA Antiarrhythmics (Highest Risk) may enhance the QTc-prolonging effect of Ceritinib. Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloroquine: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Chloroquine.  Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cimetidine: May increase the serum concentration of Procainamide. Management: Consider an alternative H2-receptor antagonist in patients taking procainamide. If combined, monitor for increased therapeutic effects/toxicity of procainamide.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Citalopram: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Citalopram. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clarithromycin: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Clarithromycin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Clofazimine.  Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ClomiPRAMINE: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of CloZAPine.  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Crizotinib: QT-prolonging Class IA Antiarrhythmics (Highest Risk) may enhance the QTc-prolonging effect of Crizotinib. Crizotinib may enhance the QTc-prolonging effect of QT-prolonging Class IA Antiarrhythmics (Highest Risk). Crizotinib may increase the serum concentration of QT-prolonging Class IA Antiarrhythmics (Highest Risk).  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabrafenib: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dasatinib: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Dasatinib.  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Domperidone: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Domperidone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxepin-Containing Products: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Doxepin-Containing Products.  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroPERidol: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of DroPERidol.  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Encorafenib: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Entrectinib: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erdafitinib: May increase the serum concentration of OCT2 Substrates (Clinically Relevant with Inhibitors). Management: Consider alternatives to this combination when possible. If combined, monitor for increased effects/toxicities of OCT2 substrates and consider OCT2 substrate dose reductions when appropriate.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erythromycin (Systemic): QT-prolonging Class IA Antiarrhythmics (Highest Risk) may enhance the QTc-prolonging effect of Erythromycin (Systemic). Erythromycin (Systemic) may enhance the QTc-prolonging effect of QT-prolonging Class IA Antiarrhythmics (Highest Risk). Erythromycin (Systemic) may increase the serum concentration of QT-prolonging Class IA Antiarrhythmics (Highest Risk).  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Escitalopram: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Escitalopram.  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etelcalcetide: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fingolimod: May enhance the QTc-prolonging effect of QT-prolonging Class IA Antiarrhythmics (Highest Risk).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flecainide: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Flecainide.  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluconazole: May enhance the QTc-prolonging effect of QT-prolonging Class IA Antiarrhythmics (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluorouracil Products: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Fluorouracil Products.  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flupentixol: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Flupentixol. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Foslevodopa: May increase the serum concentration of MATE1/2-K Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gadobenate Dimeglumine: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Gadobenate Dimeglumine.  Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gemifloxacin: May enhance the QTc-prolonging effect of QT-prolonging Class IA Antiarrhythmics (Highest Risk).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gilteritinib: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this combination. If use is necessary, monitor for QTc interval prolongation and arrhythmias.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Halofantrine: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Halofantrine.  Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: QT-prolonging Class IA Antiarrhythmics (Highest Risk) may enhance the QTc-prolonging effect of Haloperidol.  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">HydrOXYzine: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iboga: May enhance the QTc-prolonging effect of QT-prolonging Class IA Antiarrhythmics (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Imipramine: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inotuzumab Ozogamicin: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Inotuzumab Ozogamicin.  Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lacosamide: QT-prolonging Class IA Antiarrhythmics (Highest Risk) may enhance the adverse/toxic effect of Lacosamide. Specifically the risk for bradycardia, ventricular tachyarrhythmias, or a prolonged PR interval may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">LamoTRIgine: May increase the serum concentration of Procainamide. Management: Consider monitoring for increased procainamide concentrations and/or systemic effects in patients receiving procainamide with lamotrigine. The lamotrigine Canadian product monograph states that coadministration of these agents is not recommended.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Landiolol: Procainamide may enhance the adverse/toxic effect of Landiolol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levofloxacin-Containing Products (Systemic): May enhance the QTc-prolonging effect of QT-prolonging Class IA Antiarrhythmics (Highest Risk).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levoketoconazole: QT-prolonging Class IA Antiarrhythmics (Highest Risk) may enhance the QTc-prolonging effect of Levoketoconazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lofexidine: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Lofexidine.  Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Meglumine Antimoniate: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methadone: QT-prolonging Class IA Antiarrhythmics (Highest Risk) may enhance the QTc-prolonging effect of Methadone.  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midostaurin: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Midostaurin.  Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Moxifloxacin (Systemic): QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Moxifloxacin (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular-Blocking Agents: Procainamide may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nilotinib: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Nilotinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">OLANZapine: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of OLANZapine.  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ondansetron: QT-prolonging Class IA Antiarrhythmics (Highest Risk) may enhance the QTc-prolonging effect of Ondansetron.  Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Osimertinib: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Osimertinib.  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxytocin: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pacritinib: May increase the serum concentration of OCT1 Substrates (Clinically Relevant with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">PAZOPanib: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of PAZOPanib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentamidine (Systemic): QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Pentamidine (Systemic).  Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pilsicainide: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Pilsicainide.  Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimozide: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Pimozide.  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piperaquine: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Piperaquine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Probucol: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Probucol. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propafenone: May enhance the QTc-prolonging effect of QT-prolonging Class IA Antiarrhythmics (Highest Risk).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propofol: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Indeterminate Risk - Avoid): May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Indeterminate Risk - Caution): May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Class IA Antiarrhythmics (Highest Risk): May enhance the QTc-prolonging effect of other QT-prolonging Class IA Antiarrhythmics (Highest Risk).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Class III Antiarrhythmics (Highest Risk): QT-prolonging Class IA Antiarrhythmics (Highest Risk) may enhance the QTc-prolonging effect of QT-prolonging Class III Antiarrhythmics (Highest Risk). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-Prolonging Inhalational Anesthetics (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Kinase Inhibitors (Highest Risk): May enhance the QTc-prolonging effect of QT-prolonging Class IA Antiarrhythmics (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Miscellaneous Agents (Highest Risk): QT-prolonging Class IA Antiarrhythmics (Highest Risk) may enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Highest Risk).  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Strong CYP3A4 Inhibitors (Highest Risk): QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of QT-prolonging Strong CYP3A4 Inhibitors (Highest Risk).  Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QUEtiapine: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of QUEtiapine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quizartinib: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">RaNITIdine (Withdrawn from US Market): May increase the serum concentration of Procainamide. Ranitidine may also increase the concentration of the active N-acetyl-procainamide (NAPA) metabolite.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ribociclib: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Ribociclib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Risdiplam: May increase the serum concentration of MATE1/2-K Substrates (Clinically Relevant with Inhibitors). Management: Avoid use of risdiplam with MATE substrates if possible. If the combination cannot be avoided, monitor closely for adverse effects. Consider a reduced dose of the MATE substrate according to that substrate's labeling if appropriate.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">RisperiDONE: QT-prolonging Agents (Highest Risk) may enhance the CNS depressant effect of RisperiDONE. QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of RisperiDONE.  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Saquinavir: QT-prolonging Class IA Antiarrhythmics (Highest Risk) may enhance the QTc-prolonging effect of Saquinavir.  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sertindole: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sparfloxacin: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Sparfloxacin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">SUNItinib: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of SUNItinib.  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tafenoquine: May increase the serum concentration of MATE1/2-K Substrates (Clinically Relevant with Inhibitors). Management: Avoid use of MATE substrates with tafenoquine, and if the combination cannot be avoided, monitor closely for evidence of toxicity of the MATE substrate and consider a reduced dose of the MATE substrate according to that substrate's labeling.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tafenoquine: May increase the serum concentration of OCT2 Substrates (Clinically Relevant with Inhibitors). Management: Avoid use of OCT2 substrates with tafenoquine, and if the combination cannot be avoided, monitor closely for evidence of toxicity of the OCT2 substrate and consider a reduced dose of the OCT2 substrate according to that substrate's labeling.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Terbutaline: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thioridazine: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Thioridazine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Toremifene: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Toremifene.  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimethoprim: May increase serum concentrations of the active metabolite(s) of Procainamide. Trimethoprim may increase the serum concentration of Procainamide. Management: Consider alternatives to trimethoprim-containing regimens to avoid this interaction. If coadministered, monitor for increased procainamide adverse effects (increased QTc) if trimethoprim is initiated/dose increased.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vemurafenib: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Vemurafenib.  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voriconazole: QT-prolonging Class IA Antiarrhythmics (Highest Risk) may enhance the QTc-prolonging effect of Voriconazole.  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block pri drugH1Div" id="F10950407"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Procainamide crosses the placenta (Dumesic 1982; Oudijk 2002); procainamide and its active metabolite (N-acetyl procainamide) can be detected in the cord blood and neonatal serum (Pittard 1983). Intravenous procainamide may be considered for the acute treatment of SVT in pregnant women. Due to adverse events (lupus-like syndrome), long-term therapy should be avoided unless other options are not available (Page [ACC/AHA/HRS 2016]).</p></div>
<div class="block mopp drugH1Div" id="F53568492"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">ECG, blood pressure; CBC with differential and platelet counts at weekly intervals for the first 3 months of treatment, periodically thereafter, or if signs of infection, bruising or bleeding occur; antinuclear antibody test (ANA); renal function; serum drug concentrations (procainamide and NAPA) especially in patients with hepatic impairment, renal failure, or those receiving higher maintenance doses (eg, adults: &gt;3 mg/minute) for &gt;24 hours </p></div>
<div class="block rerp drugH1Div" id="F53568372"><span class="drugH1">Reference Range</span>
<p style="text-indent:0em;text-align:justify;display:inline">Timing of serum samples: Draw 6 to 12 hours after start of IV infusion; half-life is 2.5 to 5 hours in adults</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Therapeutic: Optimal ranges must be ascertained for individual patients, with ECG monitoring </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Procainamide: 4 to 10 mcg/mL (SI: 15 to 37 micromoles/L) </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Sum of procainamide and N-acetyl procainamide: 10 to 30 mcg/mL (SI: &lt;110 micromoles/L) </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Toxic (procainamide): &gt;10-12 mcg/mL (SI: &gt;37-44 micromoles/L)</p></div>
<div class="block pha drugH1Div" id="F213504"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Decreases myocardial excitability and conduction velocity and may depress myocardial contractility, by increasing the electrical stimulation threshold of ventricle, His-Purkinje system and through direct cardiac effects</p></div>
<div class="block phk drugH1Div" id="F213524"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Onset of action: IM 10 to 30 minutes </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: V<sub>d</sub>: Children: 2.2 L/kg; Adults: 2 L/kg; decreased with congestive heart failure or shock </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: 15% to 20% </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Hepatic via acetylation to produce N-acetyl procainamide (NAPA) (active metabolite)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Procainamide (hepatic acetylator, phenotype, cardiac and renal function dependent): Children: 1.7 hours; Adults: 2.5 to 4.7 hours; Anephric: 11 hours </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">NAPA (dependent upon renal function): Children: 6 hours; Adults: 6 to 8 hours; Anephric: 42 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak, serum: IM: 15 to 60 minutes </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (30% to 60% unchanged procainamide; 6% to 52% as NAPA); feces (&lt;5% unchanged procainamide. <b>Note:</b> &gt;80% of formed NAPA is renally eliminated in contrast to procainamide which is ~50% renally eliminated (Gibson, 1977).</p></div>
<div class="block phksp drugH1Div" id="F51220124"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Elimination half-life is prolonged.</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: Elimination half-life is prolonged.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038779"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Pronestyl</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Pronestyl</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Pronestyl</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Procainamid</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Procamide</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Procainamide</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Apo procainamide</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Biocoryl</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Procamid</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Pronestyl</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Procainamide | Pronestyl</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Pronestyl</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Procainamide | Pronestyl</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Procainamid</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Pronestyl</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Pronestyl</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Procamide</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Amisalin | Procainamide hcl yoshitomi | Pronestyl</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Procainamide HCL | Pulcan</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Novocainamid | Procainamid</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Novocainamid | Procainamid</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Pronestyl</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Pronestyl</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Pronestyl</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Pronestyl</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Procainamidum</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Procainamide HCL | Procanbid | Pronestyl</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Biocoryl</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Novocainamid | Novocainamide</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Pronestyl</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Procainamide</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Apo procainamide</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Pronestyl</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Procamide | Pronestyl</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Novocainamid</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Pronestyl</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Pronestyl</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-AHA.1">
<a name="AHA.1"></a>2005 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Part 7.2: management of cardiac arrest. <i>Circulation</i>. 2005;112(24)(suppl):IV58-IV66. doi:10.1161/CIRCULATIONAHA.105.166557</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29084731">
<a name="29084731"></a>Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. <i>Circulation</i>. 2018;138(13):e272-e391. doi:10.1161/CIR.0000000000000549<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/procainamide-pediatric-drug-information/abstract-text/29084731/pubmed" id="29084731" target="_blank">29084731</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.1">
<a name="Aronoff.1"></a>Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>. 5th ed. American College of Physicians; 2007:38.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bauer.1">
<a name="Bauer.1"></a>Bauer LA. Chapter 8. Procainamide/N-Acetyl Procainamide. In Applied Clinical Pharmacokinetics. 2nd ed. McGraw-Hill Medical; 2008. <a href="http://0-accesspharmacy.mhmedical.com.crusher.neomed.edu/content.aspx?bookid=510&amp;amp;sectionid=40843082" target="_blank">http://0-accesspharmacy.mhmedical.com.crusher.neomed.edu/content.aspx?bookid=510&amp;sectionid=40843082</a>. Accessed June 24, 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Boro.1">
<a name="Boro.1"></a>Boro MS, Winter M. Procainamide. In: <i>Basic Clinical Pharmacokinetics.</i> 4th edition. Lippincott Williams and Wilkins; 2004: 364.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31504425">
<a name="31504425"></a>Brugada J, Katritsis DG, Arbelo E, et al; ESC Scientific Document Group. 2019 ESC guidelines for the management of patients with supraventricular tachycardia the task force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC). <i>Eur Heart J</i>. 2020;41(5):655-720. doi:10.1093/eurheartj/ehz467<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/procainamide-pediatric-drug-information/abstract-text/31504425/pubmed" id="31504425" target="_blank">31504425</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20194798">
<a name="20194798"></a>Chang PM, Silka MJ, Moromisato DY, et al. Amiodarone Versus Procainamide for the Acute Treatment of Recurrent Supraventricular Tachycardia in Pediatric Patients. <i>Circ Arrhythm Electrophysiol</i>. 2010;3(2):134-140.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/procainamide-pediatric-drug-information/abstract-text/20194798/pubmed" id="20194798" target="_blank">20194798</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6191939">
<a name="6191939"></a>Christoff PB, Conti DR, Naylor C, Jusko WJ. Procainamide disposition in obesity. <i>Drug Intell Clin Pharm</i>. 1983;17(7-8):516-522.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/procainamide-pediatric-drug-information/abstract-text/6191939/pubmed" id="6191939" target="_blank">6191939</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6178545">
<a name="6178545"></a>Connolly SJ, Kates RE. Clinical pharmacokinetics of N-acetylprocainamide. <i>Clin Pharmacokinet</i>. 1982;7(3):206-220. doi:10.2165/00003088-198207030-00002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/procainamide-pediatric-drug-information/abstract-text/6178545/pubmed" id="6178545" target="_blank">6178545</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Coyle.1">
<a name="Coyle.1"></a>Coyle JD, Lima JJ. Procainamide. In: Evans WE, Schentag JJ, Jusko W, eds. <i>Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring</i>. 3rd Ed. Applied Therapeutics Inc; 1992.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7121530">
<a name="7121530"></a>Dumesic DA, Silverman NH, Tobias S, et al. Transplacental Cardioversion of Fetal Supraventricular Tachycardia With Procainamide. <i>N Engl J Med</i>. 1982;307(18):1128-1131.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/procainamide-pediatric-drug-information/abstract-text/7121530/pubmed" id="7121530" target="_blank">7121530</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1900101">
<a name="1900101"></a>Echt DS, Liebson PR, Mitchell LB, et al. Mortality and Morbidity in Patients Receiving Encainide, Flecainide, or Placebo: The Cardiac Arrhythmia Suppression Trial,. <i>N Engl J Med</i>. 1991;324(12):781-788.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/procainamide-pediatric-drug-information/abstract-text/1900101/pubmed" id="1900101" target="_blank">1900101</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20956217">
<a name="20956217"></a>Field JM, Hazinski MF, Sayre MR, et al. Part 1: Executive Summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation</i>. 2010;122(18)(suppl 3):640-656.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/procainamide-pediatric-drug-information/abstract-text/20956217/pubmed" id="20956217" target="_blank">20956217</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1512329">
<a name="1512329"></a>Flaker GC, Blackshear JL, McBride R, et al. Antiarrhythmic Drug Therapy and Cardiac Mortality in Atrial Fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. <i>J Am Coll Cardiol.</i> 1992;20:527-532.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/procainamide-pediatric-drug-information/abstract-text/1512329/pubmed" id="1512329" target="_blank">1512329</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1089243">
<a name="1089243"></a>Gelband H, Rosen MR. Pharmacologic basis for the treatment of cardiac arrhythmias. <i>Pediatrics</i>. 1975;55(1):59-67.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/procainamide-pediatric-drug-information/abstract-text/1089243/pubmed" id="1089243" target="_blank">1089243</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6084435">
<a name="6084435"></a>Giardina EG. Procainamide: clinical pharmacology and efficacy against ventricular arrhythmias. <i>Ann N Y Acad Sci</i>. 1984;432:177-188. doi:10.1111/j.1749-6632.1984.tb14519.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/procainamide-pediatric-drug-information/abstract-text/6084435/pubmed" id="6084435" target="_blank">6084435</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-609192">
<a name="609192"></a>Gibson TP, Atkinson AJ Jr, Matusik E, et al. Kinetics of Procainamide and N-Acetylprocainamide in Renal Failure. <i>Kidney Int</i>. 1977;12(6):422-429<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/procainamide-pediatric-drug-information/abstract-text/609192/pubmed" id="609192" target="_blank">609192</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7437202">
<a name="7437202"></a>Halpern SW, Ellrodt G, Singh BN, Mandel WJ. Efficacy of intravenous procainamide infusion in converting atrial fibrillation to sinus rhythm: relation of left atrial size. <i>Br Heart J</i>. 1980;44:589-595.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/procainamide-pediatric-drug-information/abstract-text/7437202/pubmed" id="7437202" target="_blank">7437202</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hazinski.1">
<a name="Hazinski.1"></a>Hazinski MF, Shuster M, Donnino MW, et al. <i>2015 Handbook of Emergency Cardiovascular Care for Healthcare Providers</i>. American Heart Association; 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hegenbarth.1">
<a name="Hegenbarth.1"></a>Hegenbarth MA; American Academy of Pediatrics Committee on Drugs. Preparing for pediatric emergencies: drugs to consider. <i>Pediatrics</i>. 2008;121(2):433-443.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24685669">
<a name="24685669"></a>January CT, Wann LS, Alpert JS, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. <i>J Am Coll Cardiol</i>. 2014;64(21):e1-e76. doi:10.1016/j.jacc.2014.03.022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/procainamide-pediatric-drug-information/abstract-text/24685669/pubmed" id="24685669" target="_blank">24685669</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30703530">
<a name="30703530"></a>January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. <i>Heart Rhythm</i>. 2019:S1547-5271(19)30037-2. doi:10.1016/j.hrthm.2019.01.024<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/procainamide-pediatric-drug-information/abstract-text/30703530/pubmed" id="30703530" target="_blank">30703530</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kliegman.1">
<a name="Kliegman.1"></a>Kliegman RM, St. Geme J, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Saunders Elsevier; 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20956230">
<a name="20956230"></a>Kleinman ME, Chameides L, Schexnayder SM, et al. Part 14: Pediatric Advanced Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation</i>. 2010;122(18)(suppl 3):876-908.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/procainamide-pediatric-drug-information/abstract-text/20956230/pubmed" id="20956230" target="_blank">20956230</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4554558">
<a name="4554558"></a>Koch-Weser J. Antiarrhythmic Prophylaxis in Ambulatory Patients With Coronary Heart Disease. <i>Arch Intern Med</i>. 1972;129(5):763-772.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/procainamide-pediatric-drug-information/abstract-text/4554558/pubmed" id="4554558" target="_blank">4554558</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-5107621">
<a name="5107621"></a>Koch-Weser J, Klein SW .Procainamide Dosage Schedules, Plasma Concentrations, and Clinical Effects. <i>JAMA</i>. 1971;215(9):1454-1460.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/procainamide-pediatric-drug-information/abstract-text/5107621/pubmed" id="5107621" target="_blank">5107621</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9391691">
<a name="9391691"></a>Luedtke SA, Kuhn RJ, McCaffrey FM. Pharmacologic management of supraventricular tachycardias in children. Part 2: Atrial flutter, atrial fibrillation, and junctional and atrial ectopic tachycardia. <i>Ann Pharmacother</i>. 1997;31(11):1347-1359.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/procainamide-pediatric-drug-information/abstract-text/9391691/pubmed" id="9391691" target="_blank">9391691</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10754080">
<a name="10754080"></a>Mandapati R, Byrum CJ, Kavey RE, et al. Procainamide for rate control of postsurgical junctional tachycardia. <i>Pediatr Cardiol</i>. 2000;21(2):123-128.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/procainamide-pediatric-drug-information/abstract-text/10754080/pubmed" id="10754080" target="_blank">10754080</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29685887">
<a name="29685887"></a>Marino BS, Tabbutt S, MacLaren G, et al. Cardiopulmonary resuscitation in infants and children with cardiac disease: a scientific statement from the American Heart Association. <i>Circulation</i>. 2018;137(22):e691-e782.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/procainamide-pediatric-drug-information/abstract-text/29685887/pubmed" id="29685887" target="_blank">29685887</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17125432">
<a name="17125432"></a>Moffett BS, Cannon BC, Friedman RA, et al. Therapeutic Levels of Intravenous Procainamide in Neonates: A Retrospective Assessment. <i>Pharmacotherapy</i>. 2006;26(12):1687-1693.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/procainamide-pediatric-drug-information/abstract-text/17125432/pubmed" id="17125432" target="_blank">17125432</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23562328">
<a name="23562328"></a>Mohamed AN, Abdelhady AM, Spencer D, Sowinski KM, Tisdale JE, Overholser BR. Pharmacokinetic modeling and simulation of procainamide and N-acetylprocainamide in a patient receiving continuous renal replacement therapy: a novel approach to guide renal dose adjustments. <i>Am J Kidney Dis</i>. 2013;61(6):1046-1048. doi:10.1053/j.ajkd.2013.02.358<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/procainamide-pediatric-drug-information/abstract-text/23562328/pubmed" id="23562328" target="_blank">23562328</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nelson.1996">
<a name="Nelson.1996"></a>Nelson WE, Behrman RE, Arvin AM, Kliegman RM, eds. <i>Nelson Textbook of Pediatrics</i>. 15th ed. WB Saunders Company; 1996:2058-2078.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20956224">
<a name="20956224"></a>Neumar RW, Otto CW, Link MS, et al. Part 8: Adult Advanced Cardiovascular Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation</i>. 2010;122(18)(suppl 3):729767. doi:10.1161/CIRCULATIONAHA.110.970988<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/procainamide-pediatric-drug-information/abstract-text/20956224/pubmed" id="20956224" target="_blank">20956224</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11817986">
<a name="11817986"></a>Oudijk MA, Ruskamp JM, Ambachtsheer BE, et al. Drug Treatment of Fetal Tachycardias. <i>Paediatr Drugs</i>. 2002;4(1):49-63.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/procainamide-pediatric-drug-information/abstract-text/11817986/pubmed" id="11817986" target="_blank">11817986</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26409259">
<a name="26409259"></a>Page RL, Joglar JA, Caldwell MA, et al. 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. <i>J Am Coll Cardiol</i>. 2016;67(13):e27-e115. doi:10.1016/j.jacc.2015.08.856<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/procainamide-pediatric-drug-information/abstract-text/26409259/pubmed" id="26409259" target="_blank">26409259</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33081529">
<a name="33081529"></a>Panchal AR, Bartos JA, Cabañas JG, et al; Adult Basic and Advanced Life Support Writing Group. Part 3: adult basic and advanced life support: 2020 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. <i>Circulation</i>. 2020;142(16)(suppl 2):S366-S468. doi:10.1161/CIR.0000000000000916<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/procainamide-pediatric-drug-information/abstract-text/33081529/pubmed" id="33081529" target="_blank">33081529</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Park.1">
<a name="Park.1"></a>Park, MK. <i>Park's Pediatric Cardiology for Practitioners</i>. 7th ed. Elsevier Health Sciences; 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6187910">
<a name="6187910"></a>Pittard WB III, Glazier H. Procainamide Excretion in Human Milk. <i>J Pediatr</i>. 1983;102(4):631-633.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/procainamide-pediatric-drug-information/abstract-text/6187910/pubmed" id="6187910" target="_blank">6187910</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nexus.1">
<a name="Nexus.1"></a>Procainamide [prescribing information]. Lake Forest, IL: Hospira Inc; March 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sandoz.1">
<a name="Sandoz.1"></a>Procainamide hydrochloride injection [product monograph]. Boucherville, QC, Canada: Sandoz Canada: July 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Prutkin.1">
<a name="Prutkin.1"></a>Prutkin JM. Overview of the acute management of tachyarrhythmias. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed July 24, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3228104">
<a name="3228104"></a>Raymond GG, Reed MT, Teagarden JR, et al. Stability of Procainamide Hydrochloride in Neutralized 5% Dextrose Injection. <i>Am J Hosp Pharm</i>. 1988;45(12):2513-2517.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/procainamide-pediatric-drug-information/abstract-text/3228104/pubmed" id="3228104" target="_blank">3228104</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31871244">
<a name="31871244"></a>Shenoi RP, Timm N; Committee on Drugs; Committee on Pediatric Emergency Medicine. Drugs used to treat pediatric emergencies. <i>Pediatrics</i>. 2020;145(1):e20193450.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/procainamide-pediatric-drug-information/abstract-text/31871244/pubmed" id="31871244" target="_blank">31871244</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7128001">
<a name="7128001"></a>Singh S, Gelband H, Mehta AV, et al. Procainamide Elimination Kinetics in Pediatric Patients. <i>Clin Pharmacol Ther</i>. 1982;32(5):607-611.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/procainamide-pediatric-drug-information/abstract-text/7128001/pubmed" id="7128001" target="_blank">7128001</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9120158">
<a name="9120158"></a>Walsh EP, Saul JP, Sholler GF, et al. Evaluation of a staged treatment protocol for rapid automatic junctional tachycardia after operation for congenital heart disease. <i>J Am Coll Cardiol</i>. 1997;29(5):1046-1053.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/procainamide-pediatric-drug-information/abstract-text/9120158/pubmed" id="9120158" target="_blank">9120158</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12732 Version 288.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
